Published in J Clin Pathol on February 03, 2006
Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin Exp Metastasis (2008) 1.65
Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One (2011) 1.50
The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients. Br J Cancer (2007) 1.45
E-cadherin's dark side: possible role in tumor progression. Biochim Biophys Acta (2012) 1.32
Integrin regulation of beta-catenin signaling in ovarian carcinoma. J Biol Chem (2011) 1.06
Wnt/β-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer. J Ovarian Res (2014) 0.98
Integrin beta3 down-regulates invasive features of ovarian cancer cells in SKOV3 cell subclones. J Cancer Res Clin Oncol (2008) 0.94
RNAi-mediated knock-down of arylamine N-acetyltransferase-1 expression induces E-cadherin up-regulation and cell-cell contact growth inhibition. PLoS One (2011) 0.90
The EMT (epithelial-mesenchymal-transition)-related protein expression indicates the metastatic status and prognosis in patients with ovarian cancer. J Ovarian Res (2014) 0.87
Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma. PLoS One (2011) 0.84
PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL. Blood (2014) 0.84
Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies. Cancers (Basel) (2010) 0.83
Inhibition of glycogen synthase kinase-3 increases the cytotoxicity of enzastaurin. J Invest Dermatol (2011) 0.82
Betacellulin induces Slug-mediated down-regulation of E-cadherin and cell migration in ovarian cancer cells. Oncotarget (2016) 0.81
Epithelial-mesenchymal interconversions and the regulatory function of the ZEB family during the development and progression of ovarian cancer. Oncol Lett (2016) 0.77
Reduced expression of FILIP1L, a novel WNT pathway inhibitor, is associated with poor survival, progression and chemoresistance in ovarian cancer. Oncotarget (2016) 0.75
Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol (2004) 6.20
Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol (1999) 4.04
The cadherin-catenin adhesion system in signaling and cancer. J Clin Invest (2002) 3.23
Differential nuclear translocation and transactivation potential of beta-catenin and plakoglobin. J Cell Biol (1998) 2.38
Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res (1994) 2.34
High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol (2002) 2.33
Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res (1994) 2.21
Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am J Pathol (2003) 2.18
Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res (1993) 2.09
Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res (1998) 2.01
gamma-catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of beta-catenin. Genes Dev (2000) 1.89
Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res (2001) 1.87
High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res (2000) 1.77
Association of E-cadherin and beta-catenin immunoexpression with clinicopathologic features in primary ovarian carcinomas. Hum Pathol (2004) 1.62
Regulation of beta-catenin levels and localization by overexpression of plakoglobin and inhibition of the ubiquitin-proteasome system. J Cell Biol (1997) 1.59
beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol (1999) 1.55
Expression of E-cadherin in squamous cell carcinomas of the supraglottic larynx with correlations to clinicopathological features. Eur J Cancer (2002) 1.51
Immunoreactive E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, and patients' survival. Hum Pathol (2000) 1.42
Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum Pathol (1997) 1.38
Suppression of tumorigenicity by plakoglobin: an augmenting effect of N-cadherin. J Cell Biol (1996) 1.36
Wnt-signalling pathway in ovarian epithelial tumours: increased expression of beta-catenin and GSK3beta. Br J Cancer (2003) 1.35
beta-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours. Int J Cancer (1999) 1.31
Expression of E-cadherin and beta-catenin in gastric carcinoma and its correlation with the clinicopathological features and patient survival. World J Gastroenterol (2002) 1.25
Elevated expression of E-cadherin and alpha-, beta-, and gamma-catenins in metastatic lesions compared with primary epithelial ovarian carcinomas. Hum Pathol (2004) 1.23
Co-ordinated changes in expression of cell adhesion molecules in prostate cancer. Eur J Cancer (1997) 1.21
Mutations of the beta- and gamma-catenin genes are uncommon in human lung, breast, kidney, cervical and ovarian carcinomas. Br J Cancer (2001) 1.15
CD44 expression indicates favorable prognosis in epithelial ovarian cancer. Clin Cancer Res (2003) 1.12
Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res (2002) 1.10
Significance of E-cadherin/beta-catenin complex and cyclin D1 in breast cancer. Oncol Rep (2002) 1.10
Alpha-catenin expression has prognostic value in local and locally advanced prostate cancer. Br J Cancer (1999) 1.07
Possible contribution of CD44 variant 6 and nuclear beta-catenin expression to the formation of budding tumor cells in patients with T1 colorectal carcinoma. Cancer (2001) 1.05
Clinical significance of alpha-catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer. J Clin Oncol (1998) 1.05
Co-downregulation of cell adhesion proteins alpha- and beta-catenins, p120CTN, E-cadherin, and CD44 in prostatic adenocarcinomas. Hum Pathol (2001) 1.04
Mutational analysis of beta-catenin gene in Japanese ovarian carcinomas: frequent mutations in endometrioid carcinomas. Jpn J Cancer Res (1999) 1.01
Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas. Ann Oncol (2004) 1.01
E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions. J Pathol (2000) 1.00
beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma. Gynecol Oncol (2003) 1.00
Reduced expression of plakoglobin indicates an unfavorable prognosis in subsets of patients with non-small-cell lung cancer. J Clin Oncol (1998) 1.00
Reduced expression of alpha catenin is associated with poor prognosis in colorectal carcinoma. J Clin Pathol (1999) 0.99
Immunohistochemical patterns for alpha- and beta-catenin, E- and N-cadherin expression in ovarian epithelial tumors. Gynecol Oncol (2004) 0.96
Decreased expression of alpha-catenin is associated with poor prognosis of patients with localized renal cell carcinoma. Int J Cancer (1997) 0.96
E-cadherin negatively regulates CD44-hyaluronan interaction and CD44-mediated tumor invasion and branching morphogenesis. J Biol Chem (2003) 0.95
Expression of e-cadherin and beta-catenin in human esophageal squamous cell carcinoma: relationships with prognosis. World J Gastroenterol (2003) 0.90
Loss of beta-catenin is associated with poor survival in ovarian carcinomas. Int J Gynecol Pathol (2004) 0.89
The significance of E-cadherin and alpha-, beta-, and gamma-catenin expression in surgically treated non-small cell lung cancers of 3 cm or less in size. J Thorac Cardiovasc Surg (2002) 0.87
Expression of E-cadherin and beta-catenin in primary and peritoneal metastatic ovarian carcinoma. Oncol Rep (2001) 0.86
Promoter methylation regulates cadherin switching in squamous cell carcinoma. Biochem Biophys Res Commun (2004) 0.86
E-Cadherin complex protein expression and survival in ovarian carcinoma. Gynecol Oncol (2000) 0.81
CD44s, E-cadherin and PCNA as markers for progression in renal cell carcinoma. Anticancer Res (1999) 0.80
Expression and prognostic value of alpha-, beta-, and gamma-catenins indifferentiated thyroid carcinoma. J Clin Endocrinol Metab (2000) 0.80
Beta- and gamma-catenin expression in endometrial carcinoma. Relationship with clinicopathological features and microsatellite instability. Virchows Arch (2001) 0.76
Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol (2008) 2.37
High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res (2000) 1.77
No harm from five year ingestion of oats in coeliac disease. Gut (2002) 1.75
Hyaluronan in human malignancies. Exp Cell Res (2010) 1.63
PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer (2012) 1.13
Strong Stromal Hyaluronan Expression Is Associated with PSA Recurrence in Local Prostate Cancer. Urol Int (2002) 1.12
Exposure of an infant to cervical human papillomavirus infection of the mother is common. Am J Obstet Gynecol (1997) 1.11
p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis. J Clin Pathol (2003) 1.09
Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer. Gynecol Oncol (2006) 1.09
Expression of CD 44 s, CD 44 v 3 and CD 44 v 6 in benign and malignant breast lesions: correlation and colocalization with hyaluronan. Histopathology (2005) 1.02
Expression of HER2 and its association with AP-2 in breast cancer. Eur J Cancer (2004) 0.99
Hyaluronan, CD44 and versican in epidermal keratinocyte tumours. Br J Dermatol (2003) 0.98
Inflammation and tissue damage in mouse lung by single and repeated dosing of urban air coarse and fine particles collected from six European cities. Inhal Toxicol (2010) 0.97
Nuclear beta catenin expression is related to unfavourable outcome in oropharyngeal and hypopharyngeal squamous cell carcinoma. J Clin Pathol (2001) 0.92
CD44 expression and its relationship with MMP-9, clinicopathological factors and survival in oral squamous cell carcinoma. Oral Oncol (2006) 0.92
Atherosclerosis-like lesions of the aortic valve are common in adults of all ages: a necropsy study. Heart (2005) 0.92
Reduced expression of hyaluronan is a strong indicator of poor survival in oral squamous cell carcinoma. Oral Oncol (2004) 0.91
Nutrient intakes during diets including unkilned and large amounts of oats in celiac disease. Eur J Clin Nutr (2009) 0.90
Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer. Tumour Biol (2007) 0.89
Antibiotic concentrations in liquor compared to the minimal inhibitory concentrations of isolates in paediatric bacterial meningitis. The Finnish Study Group. Chemotherapy (1991) 0.88
Versican expression in pharyngeal squamous cell carcinoma: an immunohistochemical study. J Clin Pathol (2004) 0.87
Systemic immunoresponses in mice after repeated exposure of lungs to spores of Streptomyces californicus. Clin Diagn Lab Immunol (2003) 0.86
Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families. Clin Genet (2007) 0.83
Slight respiratory irritation but not inflammation in mice exposed to (1-->3)-beta-D-glucan aerosols. Mediators Inflamm (2003) 0.82
The prognostic significance of p53 expression quantitated by computerized image analysis in epithelial ovarian cancer. Int J Gynecol Pathol (1999) 0.82
Impact of germinal center and non-germinal center phenotypes on overall and failure-free survival after high-dose chemotherapy and auto-SCT in primary diffuse large B-cell lymphoma. Bone Marrow Transplant (2008) 0.82
Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk. Br J Cancer (2011) 0.81
Bone mineral density in perimenopausal women with asthma: a population-based cross-sectional study. Am J Respir Crit Care Med (1999) 0.81
WNT-4 mRNA expression in human adrenocortical tumors and cultured adrenal cells. Horm Metab Res (2008) 0.80
Depletion of cell surface CD44 in nonmelanoma skin tumours is associated with increased expression of matrix metalloproteinase 7. Br J Dermatol (2009) 0.80
Biological and prognostic role of acid cysteine proteinase inhibitor (ACPI, cystatin A) in non-small-cell lung cancer. J Clin Pathol (2006) 0.79
Monoamniotic twin pregnancy. Acta Genet Med Gemellol (Roma) (1986) 0.79
Cotargeting of VEGFR-1 and -3 and angiopoietin receptor Tie2 reduces the growth of solid human ovarian cancer in mice. Cancer Gene Ther (2010) 0.79
Effects of aerosols from nontoxic Stachybotrys chartarum on murine airways. Inhal Toxicol (2002) 0.78
The effect of photodynamic therapy on rat urinary bladder with orthotopic urothelial carcinoma. BJU Int (2003) 0.76
Effects of mobile phone radiation on UV-induced skin tumourigenesis in ornithine decarboxylase transgenic and non-transgenic mice. Int J Radiat Biol (2003) 0.76
Elevated expression of hyaluronan and its CD44 receptor in the duodenal mucosa of coeliac patients. Histopathology (2005) 0.76
Perinatal deaths in twin pregnancy: a 22-year review. Acta Genet Med Gemellol (Roma) (1988) 0.75
The effect of hypertension in pregnancy on fetal and neonatal condition. Int J Gynaecol Obstet (1989) 0.75
The changing epidemiology of esophageal cancer in Finland and the impact of the surveillance of Barrett's esophagus in detecting esophageal adenocarcinoma. Dis Esophagus (2005) 0.75